CliffBio
biologic

Revcovi

elapegademase-lvlr

Loss of exclusivityOctober 2030projected — 12-year biologic exclusivity estimate
CompanyChiesi Usa, Inc. →View the full company profile on CliffBio

Drug detail

Brand nameRevcovi
Active ingredientelapegademase-lvlr
Strength2.4MG/1.5ML (1.6MG/ML)
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalOctober 2018
Marketing statusRx

More from Chiesi Usa, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Revcovi patent cliff — loss of exclusivity October 2030 | CliffBio